Angela Gomez-Simmonds, MD

Specialties:
Internal Medicine, Infectious Disease
Accepting New Patients
Profile Headshot

Overview

Dr. Gomez-Simmonds’ research interests entail understanding the molecular factors that potentiate the acquisition and dissemination of multidrug resistance among hospital-associated pathogens. Her current projects focus on developing sequencing-based methods for investigating the epidemiology and transmission of multidrug-resistant Gram-negative bacteria at CUIMC such as carbapenem-resistant and ESBL-producing Enterobacterales. She is particularly interested in characterizing the repertoire of antibiotic resistance genes and associated mobile genetic elements in these pathogens. Additional research interests include identifying clinical risk factors and optimal therapeutic regimens for multidrug-resistant bacterial infections and investigating the clinical and microbiome factors associated with colonization and subsequent infection with hospital-associated pathogens such as Clostridioides difficile.

Academic Appointments

  • Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • Spanish

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

180 Fort Washington Avenue
New York, NY 10032
Primary

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Cigna

  • EPO
  • Great West (National)
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • HMO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

RiverSpring

  • Special Needs

UnitedHealthcare

  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, 2008 University of Medicine and Dentistry of New Jersey
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Internal Medicine
  • Infectious Disease

Research

Dr. Gomez-Simmonds’ research interests entail understanding the molecular factors that potentiate the acquisition and dissemination of multidrug resistance among hospital-associated pathogens. Her current projects focus on developing sequencing-based methods for investigating the epidemiology and transmission of multidrug-resistant Gram-negative bacteria at CUIMC such as carbapenem-resistant and ESBL-producing Enterobacterales. She is particularly interested in characterizing the repertoire of antibiotic resistance genes and associated mobile genetic elements in these pathogens. Additional research interests include identifying clinical risk factors and optimal therapeutic regimens for multidrug-resistant bacterial infections and investigating the clinical and microbiome factors associated with colonization and subsequent infection with hospital-associated pathogens such as Clostridioides difficile.

Selected Publications

  1. Gomez-Simmonds A, Annavajhala MK, Tang N, Rozenberg FD, Ahmad M, Park H, Lopatkin AJ, Uhlemann AC. Population structure of blaKPC-harbouring IncN plasmids at a New York City medical centre and evidence for multi-species horizontal transmission. Journal of Antimicrobial Chemotherapy 2022;77:1873-1882.
  2. Zucker J*, Gomez-Simmonds A*, Purpura LJ, Shoucri S, LaSota E, Morley NE, Sovic BW, Castellon MA, Theodore DA, Bartram LL, Miko BA, Scherer ML, Meyers KA, Turner WC, Kelly M, Pavlicova M, Basaraba CN, Baldwin MR, Brodie D, Burkart KM, Bathon J, Uhlemann AC, Yin MT, Castor D*, Sobieszczyk ME* (*contributed equally). Supervised machine learning approach to identify early predictors of poor outcome in patients with COVID-19 presenting to a large quaternary care hospital in New York City. Journal of Clinical Medicine 2021;10:3523.
  3. Gomez-Simmonds A, Annavajhala MK, McConville TH, Dietz DE, Shoucri SM, Laracy JC, Rozenberg FD, Nelson B, Greendyke WG, Furuya EY, Whittier S, Uhlemann AC. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. Journal of Antimicrobial Chemotherapy 2021;76:380-384.
  4. Prensky H, Gomez-Simmonds A, Uhlemann AC, Lopatkin AJ. Conjugation dynamics depend on both the plasmid acquisition cost and the fitness cost. Molecular Systems Biology 2021;17:e9913.
  5. Nelson BC, Laracy J, Shoucri S, Dietz D, Zucker J, Patel N, Sobieszczyk ME, Kubin CJ, Gomez-Simmonds A. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19. Clinical Infectious Diseases 2020;ciaa1163.
  6. Annavajhala MK, Gomez-Simmonds A, Macesic N, Sullivan SB, Kress A, Khan SD, Giddins MJ, Stump S, Kim GI, Narain R, Verna EC, Uhlemann AC. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. Nature Communications. 2019;10:4715.
  7. Annavajhala MK, Gomez-Simmonds A, Uhlemann AC. Multidrug-Resistant Enterobacter cloacae Complex Emerging as a Global, Diversifying Threat. Front Microbiol. 2019;10:44.
  8. Gomez-Simmonds A, Stump S, Giddins MJ, Annavajhala MK, Uhlemann AC.
  9. Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2018;628:e00573-18.
  10. Gomez-Simmonds A*, Annavajhala MK*, Wang Z*, Macesic N, Hu Y, Giddins MJ, O'Malley A, Toussaint NC, Whittier S, Torres VJ, Uhlemann AC (*contributed equally). Genomic and geographic context for the evolution of high-risk carbapenem-resistant Enterobacter cloacae complex clones ST171 and ST78. MBio 2018;93:e00542-18.
  11. Macesic N, Gomez-Simmonds A, Sullivan SB, Giddins MJ, Ferguson SA, Korakavi G, Leeds D, Park S, Shim K, Sowash MG, Hofbauer M, Finkel R, Hu Y, West J, Toussaint NC, Greendyke WG, Miko BA, Pereira MR, Whittier S, Verna EC, Uhlemann AC. Genomic surveillance reveals diversity of multidrug-resistant organism colonization and infection: a prospective cohort study in liver transplant recipients. Clinical Infectious Diseases 2018;67:905-912.
  12. Gomez-Simmonds A, Uhlemann AC. Clinical Implications of Genomic Adaptation and Evolution of Carbapenem-Resistant Klebsiella pneumoniae. Resistant Klebsiella pneumoniae. Journal of Infectious Diseases 2017;215:S18-S27.
  13. Gomez-Simmonds A, Hu Y, Sullivan SB, Wang Z, Whittier S, Uhlemann AC. Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007-14. Journal of Antimicrobial Chemotherapy 2016;71:2351-3.
  14. Gomez-Simmonds A, Nelson B, Eiras D, Loo A, Jenkins SG, Whittier S, Calfee DP, Satlin M, Kubin CJ, Furuya EY. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Antimicrobial Agents and Chemotherapy 2016;60:3601-7.
  15. Gomez-Simmonds A, Greenman M, Sowash M, Sullivan SB, Tanner J, Uhlemann AC. Population structure of Klebsiella pneumoniae causing bloodstream infections at a New York City tertiary care hospital: diversification of multidrug-resistant isolates. Journal of Clinical Microbiology 2015;53:2060-7.